COVID - search results

Researchers from four NIH institutes and centers plan to collect and analyze blood samples from up to 10,000 volunteers, with the aim of providing critical data for epidemiological models.

The first lab was installed recently at the Shenzhen National GeneBank and was developed in response to the need for countries to rapidly build-up screening and testing infrastructure in response to the COVID-19 pandemic.

SARS-CoV-2 uses the ACE-2 receptor as a cellular entry receptor, the authors wrote. While the virus can infect people of any age, most of the severe cases, to date, have been in individuals over the age of 55 years and with significant comorbidities, such as COPD.

The studies showed that the drug, ivermectin, started to become effective against SARS-CoV-2 in lab-grown cells within just a day and “could essentially remove all viral RNA by 48 hours,” researchers said.

According to the company, the test will run on its FDA-approved ARIES system, an automated platform that can run up to 144 tests per day and deliver results in about two hours.

MIT engineers have developed nanoparticles that can be delivered to the lungs, where tumor-associated proteases cut peptides on the surface of the particles, releasing reporter molecules. Those reporters can be detected by a urine test.

The collaboration will provide a COVID-19 test offering that combines Paragon Genomics' CleanPlex SARS-CoV-2 NGS panel reagent kit for whole-genome sequencing of the coronavirus with the advanced analytical power of the SOPHiA platform.

As Moderna's vaccine development moves at unprecedented speed, the company's CEO explains how they have moved so quickly and why he is hopeful that their pace will continue.

Scripps researchers compare available genome sequence data for known coronavirus strains to determine that that SARS-CoV-2 originated through natural processes and note that their results “clearly show that SARS-CoV-2 is not a laboratory construct or a purposefully manipulated virus.”

“We found that the stability of SARS-CoV-2 was similar to that of SARS-CoV-1 under the experimental circumstances tested,” the authors wrote. “This indicates that differences in the epidemiologic characteristics of these viruses probably arise from other factors."